Chemotherapy and Biological Therapy for Advanced Mesothelioma
Name of the Trial
Why Is This Trial Important?
In this study, researchers are adding a biological agent called bevacizumab (Avastin) to chemotherapy to see if it can help delay the progression of mesothelioma in patients with advanced disease. Bevacizumab is a monoclonal antibody that blocks the action of a protein called vascular endothelial growth factor (VEGF). In mesothelioma, VEGF may stimulate both tumor cell growth and the formation of tumor blood vessels.
"Bevacizumab has shown promise in several other types of cancer, and we hope that it will be particularly effective against mesothelioma because VEGF plays such a prominent role in the growth of this disease," said Dr. Kindler. "Additionally, bevacizumab works synergistically with chemotherapy, so combining these treatments may yield better results than either chemotherapy or biological therapy alone."
"Because mesothelioma is an orphan disease, there often isn't the incentive to pursue new therapies for it, so we are very pleased that NCI is supporting such a study," Dr. Kindler added.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.